Last €225.56 EUR
Change Today -1.14 / -0.50%
Volume 5.7K
As of 3:24 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/30/14 - €232.28
52 Week Low
12/16/13 - €188.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ROCHE HOLDING AG-BR (RHO)

roche holding ag-br (RHO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RHO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RHO) Key Developments

Roche to Invest CHF 3 Billion in Basel Site in Switzerland over the Coming Ten Years

Roche is set to invest CHF 3 billion in its Basel site in Switzerland over the coming ten years. The company has noted that it will invest in modern research infrastructure, attractive workplaces, and sustainable site development. The investment in construction of a new building and an upgrading of the existing facilities is meant to consolidate the company's 9,000 employees who are spread around the city at the main site. Apart from using the existing site more efficiently, the employee consolidation is also intended to enable communication and interaction between the company's employees, including the research staff. The announcement of the CHF 3 billion investment in its Basel site follows Roche's announcement in June that it would invest CHF 120 million in construction of new manufacturing facilities, which are also at its Basel site. The investment comprises a CHF 85 million new facility for chemically manufactured drugs, as well as CHF 35 million aimed for expansion of its multipurpose unit where investigational drugs are manufactured. Apart from Basel plans, the investment will include CHF 350 million that will be allocated to Penzberg and CHF 260 million will be injected into Vacaville and Oceanside. This investment distribution represents the desire to strengthen the company's manufacturing network that produces novel biological molecules. The investments also represent Roche's intent to not only invest in its research and manufacturing capabilities but also in human capital in order to enable innovativeness and sustain its sales' performance.

Roche Holding AG Reports Group Sales Results for the Third Quarter and Nine Months Ended September 2014; Provides Earnings Guidance for the Full Year of 2014

Roche Holding AG reported group sales results for the third quarter and nine months ended September 2014. For the period, the company reported group sales of CHF 34,757 million against CHF 34,867 million a year ago. For the third quarter, Roche's sales increased 1.8% from the similar period a year ago. The company posted sales of CHF 11.78 billion for July to September, up from CHF 11.57 billion a year earlier. For the full year 2014, the company expects low- to mid-single digit growth in Group sales at constant exchange rates. Core Earnings per share is targeted to grow ahead of sales.

Roche Say No To Mega-Merger

Roche Holding AG (SWX:ROG) will not consider launching a "mega-merger" in the pharmaceutical sector and instead focus on targeted opportunities to grow, Chief Executive Severin Schwan said. "We are screening the market for very targeted opportunities where we can build our existing franchises be it in diagnostics or pharma or technologies or products. but we are not into mega-mergers, we have a very targeted approach." Shares of Roche rose 1.95%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO:GR €225.56 EUR -1.14

RHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €112.78 EUR +2.36
General Electric Co $25.81 USD +0.14
Gilead Sciences Inc $112.00 USD -2.22
Merck & Co Inc $57.94 USD +0.63
Novartis AG SFr.89.30 CHF +1.60
View Industry Companies

Industry Analysis


Industry Average

Valuation RHO Industry Range
Price/Earnings 21.1x
Price/Sales 4.6x
Price/Book 12.8x
Price/Cash Flow 17.2x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at